Hyperresponsivity to Low-Dose Endotoxin during Progression to Nonalcoholic Steatohepatitis Is Regulated by Leptin-Mediated Signaling

被引:296
作者
Imajo, Kento [1 ]
Fujita, Koji [1 ]
Yoneda, Masato [1 ]
Nozaki, Yuichi [1 ]
Ogawa, Yuji [1 ]
Shinohara, Yoshiyasu [1 ]
Kato, Shingo [1 ]
Mawatari, Hironori [1 ]
Shibata, Wataru [1 ]
Kitani, Hiroshi [2 ]
Ikejima, Kenichi [3 ]
Kirikoshi, Hiroyuki [1 ]
Nakajima, Noriko [4 ]
Saito, Satoru [1 ]
Maeyama, Shiro [5 ]
Watanabe, Sumio [3 ]
Wada, Koichiro [6 ]
Nakajima, Atsushi [1 ]
机构
[1] Yokohama City Univ, Grad Sch Med, Dept Gastroenterol, Yokohama, Kanagawa 232, Japan
[2] Natl Inst Agrobiol Sci, Transgen Anim Res Ctr, Tsukuba, Ibaraki, Japan
[3] Juntendo Univ, Sch Med, Dept Gastroenterol, Bunkyo Ku, Tokyo, Japan
[4] Natl Inst Infect Dis, Dept Pathol, Shinjuku Ku, Tokyo, Japan
[5] Kitakahiwa Rehabil Hosp, Kashiwa, Chiba, Japan
[6] Osaka Univ, Grad Sch Dent, Dept Pharmacol, Suita, Osaka, Japan
基金
日本科学技术振兴机构;
关键词
FATTY LIVER-DISEASE; NATURAL-HISTORY; CD14; INFLAMMATION; RECEPTOR; LIPOPOLYSACCHARIDE; ASSOCIATION; ACTIVATION; PROTEIN; OBESITY;
D O I
10.1016/j.cmet.2012.05.012
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Although bacterial endotoxin, such as lipopolysaccharide (LPS), plays a key role in the pathogenesis of nonalcoholic steatohepatitis (NASH), detailed mechanisms of this pathogenesis remain unclear. Here, we demonstrate that upregulation of CD14 by leptin-mediated signaling is critical to hyperreactivity against endotoxin during NASH progression. Upregulation of CD14 in Kupffer cells and hyperreactivity against low-dose LPS were observed in high-fat diet (HFD)-induced steatosis mice, but not chow-fed-control mice. Hyperresponsivity against low-dose LPS led to accelerated NASH progression, including liver inflammation and fibrosis. Administering leptin in chow-fed mice caused increased hepatic expression of CD14 via STAT3 signaling, resulting in hyperreactivity against low-dose LPS without steatosis. In contrast, a marked decrease in hepatic CD14 expression was observed in leptin-deficient ob/ob mice, despite severe steatosis. Our results indicate that obesity-induced leptin plays a crucial role in NASH progression via enhanced responsivity to endotoxin, and we propose a mechanism of bacteria-mediated progression of NASH.
引用
收藏
页码:44 / 54
页数:11
相关论文
共 40 条
[1]   Small Intestinal Bacterial Overgrowth in Nonalcoholic Steatohepatitis: Association with Toll-Like Receptor 4 Expression and Plasma Levels of Interleukin 8 [J].
Abu Shanab, Ahmed ;
Scully, Paul ;
Crosbie, Orla ;
Buckley, Martin ;
O'Mahony, Liam ;
Shanahan, Fergus ;
Gazareen, Sanaa ;
Murphy, Eileen ;
Quigley, Eamonn M. M. .
DIGESTIVE DISEASES AND SCIENCES, 2011, 56 (05) :1524-1534
[2]   Nonalcoholic fatty liver disease [J].
Brunt, Elizabeth M. ;
Wong, Vincent W. -S. ;
Nobili, Valerio ;
Day, Christopher P. ;
Sookoian, Silvia ;
Maher, Jacquelyn J. ;
Bugianesi, Elisabetta ;
Sirlin, Claude B. ;
Neuschwander-Tetri, BrentA. ;
Rinella, Mary E. .
NATURE REVIEWS DISEASE PRIMERS, 2015, 1
[3]   Activation of downstream signals by the long form of the leptin receptor [J].
Banks, AS ;
Davis, SM ;
Bates, SH ;
Myers, MG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (19) :14563-14572
[4]   Increased risk of NASH in patients carrying the C(-159) T polymorphism in the CD14 gene promoter region [J].
Brun, P. ;
Castagliuolo, I. ;
Floreani, A. R. ;
Buda, A. ;
Blasone, L. ;
Palu, G. ;
Martines, D. .
GUT, 2006, 55 (08) :1212-1212
[5]  
Brunt EM, 1999, AM J GASTROENTEROL, V94, P2467, DOI 10.1111/j.1572-0241.1999.01377.x
[6]   Etiopathogenesis of nonalcoholic steatohepatitis [J].
Chitturi, S ;
Farrell, GC .
SEMINARS IN LIVER DISEASE, 2001, 21 (01) :27-41
[7]   Nonalcoholic fatty liver disease [J].
Clark, JM ;
Brancati, FL ;
Diehl, AM .
GASTROENTEROLOGY, 2002, 122 (06) :1649-1657
[8]   Serum immunoreactive leptin concentrations in normal-weight and obese humans [J].
Considine, RV ;
Sinha, MK ;
Heiman, ML ;
Kriauciunas, A ;
Stephens, TW ;
Nyce, MR ;
Ohannesian, JP ;
Marco, CC ;
McKee, LJ ;
Bauer, TL ;
Caro, JF .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :292-295
[9]  
Day C P, 2002, J Gastroenterol Hepatol, V17 Suppl 3, pS377, DOI 10.1046/j.1440-1746.17.s3.31.x
[10]   Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? [J].
Day, CP .
GUT, 2002, 50 (05) :585-588